Prediction, prioritization and validation of body fluid biomarkers for cancer and cardiovascular diseases

Schrift Standard Fett
Login

Forschungsstelle

INNOSUISSE

Projektnummer

12396.1;13 PFLS-LS

Projekttitel

Prediction, prioritization and validation of body fluid biomarkers for cancer and cardiovascular diseases

Projekttitel Englisch

Prediction, prioritization and validation of body fluid biomarkers for cancer and cardiovascular diseases

Texte zu diesem Projekt

	Deutsch	Französisch	Italienisch	Englisch
Kurzbeschreibung	-	-	-
Abstract	-	-	-

Erfasste Texte

Kategorie	Text
Kurzbeschreibung (Englisch)	Prediction, prioritization and validation of body fluid biomarkers for cancer and cardiovascular diseases
Abstract (Englisch)	In this follow-up project, we will generate immediate and high commercial value from the previous KTI project by discovering, prioritizing, and validating potential mRNA and protein biomarkers for applications on body fluids. In a first step, we will adjust our existing data mining engine to optimally integrate the biomarker prediction workflow for this project. This will be achieved together with a network of project partners from ETH, USZ, and several start-up companies. In a second step, we will use this pipeline for biomarker discovery in cardiovascular diseases (together with USZ) and cancer (together with ETH, ProteoMediX, Diagnoplex and Biognosys). We show in Appendix II and III several proofs of principle for various scenarios using our existing tools.

Kategorie

Text

Kurzbeschreibung
(Englisch)

Prediction, prioritization and validation of body fluid biomarkers for cancer and cardiovascular diseases

Abstract
(Englisch)

In this follow-up project, we will generate immediate and high commercial value from the previous KTI project by discovering, prioritizing, and validating potential mRNA and protein biomarkers for applications on body fluids. In a first step, we will adjust our existing data mining engine to optimally integrate the biomarker prediction workflow for this project. This will be achieved together with a network of project partners from ETH, USZ, and several start-up companies. In a second step, we will use this pipeline for biomarker discovery in cardiovascular diseases (together with USZ) and cancer (together with ETH, ProteoMediX, Diagnoplex and Biognosys). We show in Appendix II and III several proofs of principle for various scenarios using our existing tools.